• Something wrong with this record ?

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

O. Fiala, V. Veskrnova, R. Chloupkova, A. Poprach, I. Kiss, K. Kopeckova, L. Dusek, L. Slavicek, M. Kohoutek, J. Finek, M. Svoboda, L. Petruzelka, L. Boubliková, J. Dvorak, B. Melichar, T. Buchler,

. 2018 ; 13 (6) : 735-743. [pub] -

Language English Country France

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19034949
E-resources Online Full text

NLK ProQuest Central from 2006-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2006-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2006-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2006-01-01 to 1 year ago
Family Health Database (ProQuest) from 2006-01-01 to 1 year ago

Links

PubMed 30353488
DOI 10.1007/s11523-018-0597-7
Knihovny.cz E-resources

BACKGROUND: The addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results. OBJECTIVE: To determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens. PATIENTS AND METHODS: Clinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n = 401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n = 71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n = 101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle. RESULTS: Three hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2 months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5 months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6 months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9 months (95% CI 28.6-47.3) for cohort C, respectively. CONCLUSIONS: Delayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034949
003      
CZ-PrNML
005      
20191017093134.0
007      
ta
008      
191007s2018 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11523-018-0597-7 $2 doi
035    __
$a (PubMed)30353488
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Fiala, Ondrej $u Department of Oncology, University Hospital, Svobody 80, 304 60, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
245    10
$a Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis / $c O. Fiala, V. Veskrnova, R. Chloupkova, A. Poprach, I. Kiss, K. Kopeckova, L. Dusek, L. Slavicek, M. Kohoutek, J. Finek, M. Svoboda, L. Petruzelka, L. Boubliková, J. Dvorak, B. Melichar, T. Buchler,
520    9_
$a BACKGROUND: The addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results. OBJECTIVE: To determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens. PATIENTS AND METHODS: Clinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n = 401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n = 71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n = 101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle. RESULTS: Three hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2 months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5 months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6 months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9 months (95% CI 28.6-47.3) for cohort C, respectively. CONCLUSIONS: Delayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x farmakologie $x terapeutické užití $7 D000911
650    _2
$a kolorektální nádory $x farmakoterapie $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Veskrnova, Veronika $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
700    1_
$a Chloupkova, Renata $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Netroufalky 5, 625 00, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 543/7, 656 53, Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 543/7, 656 53, Brno, Czech Republic.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Motol University Hospital and Second Faculty of Medicine, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Netroufalky 5, 625 00, Brno, Czech Republic.
700    1_
$a Slavicek, Lubomir $u Department of Oncology, Jihlava Hospital Comprehensive Cancer Centre, Jihlava, Czech Republic.
700    1_
$a Kohoutek, Milan $u Department of Oncology, T Bata Hospital and Comprehensive Cancer Centre, Zlin, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology, University Hospital, Svobody 80, 304 60, Pilsen, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 543/7, 656 53, Brno, Czech Republic.
700    1_
$a Petruzelka, Lubos $u Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, U Nemocnice 499/2, 128 08, Prague, Czech Republic.
700    1_
$a Boubliková, Ludmila $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
700    1_
$a Dvorak, Josef $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic. tomas.buchler@ftn.cz.
773    0_
$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 13, č. 6 (2018), s. 735-743
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30353488 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191017093602 $b ABA008
999    __
$a ok $b bmc $g 1451609 $s 1073499
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 13 $c 6 $d 735-743 $e - $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options